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Antimicrobials are essential for the medical care and health of animals and livestock populations. On 
the other hand it is generally accepted that the increase in prevalence of antimicrobial resistance is a 
worldwide problem. Therefore, in many countries of the world, the consumption of antibiotics and the 
resistance of pathogens isolated from humans and animals are monitored. Collected data indicate the need 
to reduce antimicrobial use in humans and in food-producing animals. This goal can only be achieved if 
antimicrobials will be used rationally and in accordance with the latest knowledge. 
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Introduction 
 
In the pre-antibiotic era, infectious diseases accounted 
for significant morbidity and mortality, and invasive med-
ical procedures were fraught with the risk of infection. All 
this changed after the discovery of antimicrobials. The 
introduction of antibiotic therapy in the treatment of bac-
terial infections is considered to be the greatest scientific 
achievement of the twentieth century (Gupta et al., 2015). 
The importance of this fact can provide the award of the 
Nobel Prize (in 1945) in the field of physiology or medi-
cine to Alexander Fleming, Howard Florey and Ernst 
Chain for the discovery of penicillin and its curative ef-
fect in various infectious diseases (The Nobel Prize in 
Physiology or Medicine 1945). In 1952, Selman Waks-
man was awarded the Nobel Prize for discovery of strep-
tomycin, the first antibiotic effective against tuberculosis 
(The Nobel Prize in Physiology or Medicine 1952). Due 
to the fact that currently synthetic antimicrobial drugs are 
also called antibiotics, we should remember about the 
Nobel Prize awarded to Gerhard Domagk in 1939 for the 
discovery of the antibacterial effects of prontosil (The 
Nobel Prize in Physiology or Medicine 1939), a red dye-
stuff which is a derivative of sulphanilamide. Thus, within 
ten years (in 1940–1942 the prize was not awarded) scien-
tists engaged in research related to antibacterial therapy 
have been awarded three times. However, the discoverer 
of the first antibiotic, Alexander Fleming, warned against 
the imprudent use of penicillin, which could lead to re-
sistance to this drug. Currently it has been generally ac-
cepted that bacterial resistance to antibiotics is primarily a 
consequence of their consumption. Where they are rarely 
used resistant bacteria is less or appear sporadically. 
At the moment, antibiotic resistance is one of the most 
important global public health threat because it reduces 
the effectiveness of the therapy, extends its duration, 
increases mortality due to bacterial infections and gener-
ates huge costs resulting from it. The importance of this 
phenomenon is noticed all over the world (and especially 
in Europe) by strategic institutions for public health such 
as: World Health Organization (WHO), European Center 
for Disease Prevention and Control (ECDC), European 
Food Safety Authority (EFSA) and European Medicines 
Agency (EMA). The last three European agencies pub-
lished in 2017 (at the request of the European Commis-
sion) (European Commission, 2016) «Joint Interagency 
Antimicrobial Consumption and Resistance Analysis 
(JIACRA) Report» showing consumption of antibiotics in 
Europe in the period 2013–2015 and the occurrence of 
drug resistance among bacteria isolated from humans and 
in food-producing animals (ECDC…, 2017). In 2013 the 
consumption of antimicrobials in 26 European countries 
amounted to 11872 tons of which 3809 tons were used in 
humans and 8063 tons in food-producing animals. In the 
same year in Poland 819 tons of antibiotics were used of 
which 242 tons in humans and 577 tons in food-producing 
animals. In 2014, in 28 European countries 3821 tons of 
antibiotics were used in humans and 8927 tons in animals; 
in Poland 263 and 578 tons of antibiotics were used in 
humans and food-producing animals, respectively. The 
above data indicate that both in Europe and in Poland, the 
total consumption of antibiotics was higher in food-
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producing animals than in humans. Also, the average total 
consumption of antimicrobials in 2014 expressed in milli-
grams of active substance per kilogram of estimated bio-
mass (calculated on the basis of the number of inhabit-
ants/individuals multiplied by body weight) was higher in 
animals (152 mg/kg) than in humans (124 mg/kg), how-
ever, there were large differences between individual 
countries (ECDC…, 2017). The consumption of antibiot-
ics was lower in food-producing animals than in humans 
in 18 of 28 countries, in two it was similar, and in eight 
was higher or much higher in food-producing animals 
than in humans (including Poland were 110.7 mg/kg and 
140.8 mg/kg antimicrobials were used in humans and  
food-producing animals, respectively). Analysis of the 
consumption and antibiotic resistance of drugs from indi-
vidual therapeutic groups showed that third and fourth 
generation cephalosporins were used mainly in humans 
(especially hospitalized), which was significantly associ-
ated with the resistance of Escherichia (E.) coli isolated 
from humans to the third generation of cephalosporins. 
Furthermore, a significant relationship was found between 
consumption of the new-generation cephalosporins and 
resistance of E. coli and Salmonella spp. isolated from 
animals to the third-generation cephalosporins (ECDC…, 
2017). In the case of carbapenems, which in Europe are 
not registered for use in food-producing animals, a signif-
icant correlation has been observed between their con-
sumption in humans and resistance of K. pneumoniae 
isolated from patients. In food-producing animals, only 
very rare isolates of E. coli and Salmonella spp. resistant 
to carbapenems were found (ECDC…, 2017). The con-
sumption of tetracyclines in most countries was signifi-
cantly higher in food-producing animals than in humans, 
with significant fluctuations in their use in food-
producing animals in individual countries. Significant 
correlations between the consumption of tetracyclines in 
humans and resistance to these drugs have been found in 
Salmonella spp. and Campylobacter spp. isolated from 
patients. Significant dependence was also found between 
the consumption of tetracyclines in food-producing ani-
mals and the resistance of E. coli, Salmonella spp. and C. 
jejuni isolated from them in years 2013–2015. In addition, 
a significant relationship was found between the con-
sumption of tetracyclines in food-producing animals and 
C. jejuni resistance isolated from humans (ECDC…, 
2017). The consumption of macrolides was similar in 
food-producing animals and humans, although there were 
differences in individual countries. In humans, macrolides 
were used mainly in the community and there were no 
significant relationships between their intake and re-
sistance of Campylobacter spp. isolated from patients. 
However, a significant relationship was found between 
the consumption of macrolides in food-producing animals 
and the resistance of C. coli isolated from them in the 
years 2014–2015. In addition, there was a significant 
relationship between the consumption of macrolides in 
food-producing animals and resistance of C. jejuni and 
C. coli isolated from humans (ECDC…, 2017). In the 
case of polymyxins (mainly colistin), their consumption 
was significantly higher in food-producing animals than 
in humans, but there were large differences in the use of 
this group of drugs in animals in individual countries 
(polymyxins are not used in several countries). At the 
same time, a significant correlation was found between 
the use of polymyxins and the resistance occurring in 
E. coli isolated from food-producing animals, despite the 
fact that resistance to polymyxins in animals is usually 
low. In the case of humans, a significant relationship was 
found between the use of polymyxins in hospitals and 
Klebsiella (K.) pneumoniae resistance, while no relation-
ship was found for polymyxins used in the community 
(ECDC…, 2017). Also, consumption of fluoroquinolones 
in most countries was higher in humans than in food-
producing animals, and the differences were smaller than 
in the case of cephalosporins. The use of fluoroquinolones 
in humans (which mostly occurs in the community) was 
significantly associated with human-isolated E. coli re-
sistance, but this relationship was not found for Salmonel-
la spp. and Campylobacter (C.) spp. An important rela-
tionship was found between the use of quinolones in 
food-producing animals and the resistance of E. coli, 
Salmonella spp., C. jejuni and C. coli in years 2013–2015. 
An important relationship was also found between the use 
of quinolones in food-producing animals and the re-
sistance of E. coli, C. jejuni and C. coli isolated from 
humans (ECDC…, 2017). The obtained data indicate a 
greater correlation between the consumption of antibiotics 
and resistance occurring in E. coli than Salmonella spp. 
Moreover, they also confirmed the occurrence of E.coli 
resistance to tetracyclines and third and fourth generation 
cephalosporins in food-producing animals. In order to 
further knowledge of the current situation the data on the 
occurrence of resistance in E. coli isolated from healthy 
people would probably be a good indicator showing the 
relative exposure to drug-resistant bacteria resulting from 
food intake and direct consumption of antibiotics in the 
community. Moreover, the ability to compare commensal 
E. coli in humans and and food-producing animals might 
be useful in a multivariate analysis approach the results of 
which would be important for the «One Health» concept. 
Development of resistance is a complex phenomenon 
and is associated not only with the consumption of antibi-
otics but also includes a number of other factors (Cheng et 
al., 2015). Therefore, factors such as people traveling, 
transfer of patients between hospitals, intra-and inter-
animal trade, import and trade of food, food of non-
animal origin or exposure of humans and animals to envi-
ronmental factors should be taken into account in the drug 
resistance analysis. Another extremely important factor 
contributing to the emergence of drug resistance is the 
interaction between a pathogen (which may produce a 
different type of resistance), a drug (which may have 
different pharmacokinetic parameters) and an infected 
organism (who can have a differently functioning immune 
system, organ failure and can be treated with other drugs 
at the same time). Each of these elements reflects a dy-
namic system that can affect the effectiveness of therapy. 
Equally important in rational antibiotic therapy is the 
current knowledge of the veterinarian, who decides about 
antibacterial treatment. The optimal antibiotic should be 
characterized by: a) a narrow spectrum of action, b) a 
high therapeutic index and c) if necessary, good penetra-
tion into the tissues (Hansen and Kietzmann, 2012). Un-
fortunately, antimicrobials are not always used appropri-
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ately (wrong indication or choice of the antibiotics, inad-
equate dose and/or duration time). Therefore, for imple-
mentation a rational antimicrobial treatment regimen, 
practitioners should answer themselves for the following 
questions: 1) Does the diagnosis indicate that antimicro-
bial therapy is required? 2) What criteria should be con-
sidered when choosing an antibiotic (e.g. type and spec-
trum of activity)? 3) What pathogens are responsible for 
the infection? 4) What is the sensitivity of pathogens to 
antibiotics? 5) In what part of the body or tissue is the 
infection located? 6) What interactions may be expected? 
7) What adverse drug reactions or toxicities can be 
expected? 8) How long the antibiotic should be adminis-
tered? (Jaroszewski, 2014). In rational antibiotic therapy, 
the use of antimicrobials is only justified in cases in 
which they are actually necessary and when a careful 
choice of the active substance to achieve the purpose of 
treatment has been made. In 2015, the European Commis-
sion published «Guidelines for the use of antimicrobials 
in veterinary medicine», which indicates that prudent use 
of antimicrobials should lead to more rational and target-
ed use, thereby maximising the therapeutic effect and 
minimising the development of antimicrobial resistance 
(Commission notice, 2015). This effect will be possible to 
obtain through an overall reduction of antimicrobials 
consumption, predominantly by limiting their use only to 
situations where they are necessary. It follows that anti-
microbials should be used as targeted treatment and ac-
cording to best practices, i.e. based on clinical diagnosis 
and, whenever possible, on the results of microbiological 
susceptibility tests, and using an antimicrobial agent of as 
narrow-spectrum as possible. The document also indicates 
that antimicrobial metaphylaxis should be prescribed only 
when there is a real need for treatment and routine 
prophylaxis must be avoided. Also the off-label use (cas-
cade) should be avoided and strictly limited to very ex-
ceptional cases. When possible, alternative strategies for 
controlling the development of diseases (e.g. vaccina-
tions) should be preferred over antimicrobial treatment. 
In summary, the available data confirm the link with 
the occurrence of antibiotic consumption and antimicrobi-
al resistance of pathogens isolated both from humans and 
animals. Therefore, activities leading to limited and ra-
tional use of antibiotics from all therapeutic groups may 
reduce the spread of resistance of human and animal 
pathogens. 
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